9 results match your criteria: "Georges Francois Leclerc Centre - UNICANCER[Affiliation]"
Influenza Other Respir Viruses
November 2023
Epidemiology and Quality of Life Research Unit, INSERM U1231 Georges Francois Leclerc Centre-UNICANCER Dijon France.
Background: This study aimed to estimate the anti-SARS-CoV-2 antibody seroprevalence in the general population of Bobo-Dioulasso and Ouagadougou (Burkina Faso).
Methods: We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero-epidemiological investigations protocols and tested them with WANTAI SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio-demographic and clinical characteristics and information on exposure to SARS-CoV-2.
Int J Public Health
September 2023
UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, INSERM, Université de Bourgogne-Franche-Comté, Etablissement Français du Sang Bourgogne-Franche-Comté, Besançon, France.
To assess health-related quality of life (QoL) in caregivers of elderly patients with chronic disabilities receiving, or not receiving, social worker support. This multicenter open-label randomized study assigned caregivers to receive an information booklet, exclusively, or with social worker support. Caregivers completed Short Form-36 (SF-36) and Hospital Anxiety Depression Scale quarterly, and Zarit Burden Interview each semester, for 24 months.
View Article and Find Full Text PDFBMC Infect Dis
June 2023
Centre MURAZ, Institut National de Santé Publique (INSP), BP 390, Bobo-Dioulasso, Burkina Faso.
Background: Early data on COVID-19 (based primarily on PCR testing) indicated a low burden in Sub-Saharan Africa. To better understand this, this study aimed to estimate the incidence rate and identify predictors of SARS-CoV-2 seroconversion in the two largest cities of Burkina Faso. This study is part of the EmulCOVID-19 project (ANRS-COV13).
View Article and Find Full Text PDFCancers (Basel)
November 2022
Biostatistics and Bioinformatics (DIM), University Hospital, BP 77908, 21079 Dijon, France.
Gynecol Obstet Fertil Senol
December 2022
Service de gynécologie-obstétrique, hôpital de la Croix Rousse, hospices civiles de Lyon, Lyon, France; Inserm U1032, LabTAU, université Lyon 1, Lyon, France.
Objective: The objective of this research was to study the evolution of the mastectomy rate in patients with breast cancer between 1998 and 2015, based on population data from the Côte d'Or breast cancer registry of the FRANCIM network ("France cancer incidence and mortality").
Methods: In this study on population register we included patients who had presented a primary breast cancer (invasive cancer and/or carcinoma in situ [CIS]) between 1998 and 2015 in the Côte d'Or department. We estimated the annual proportions of mastectomies, then calculated their evolution trends over this period.
BMC Infect Dis
September 2021
Epidemiology and Quality of Life Research Unit, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, Dijon, France.
Background: The world has high hopes of vaccination against COVID-19 to protect the population, boost economies and return to normal life. Vaccination programmes are being rolled out in high income countries, but the pandemic continues to progress in many low-and middle-income countries (LMICs) despite implementation of strict hygiene measures. We aim to present a comprehensive research protocol that will generate epidemiological, sociological and anthropological data about the COVID-19 epidemic in Burkina Faso, a landlocked country in West Africa with scarce resources.
View Article and Find Full Text PDFBreast
October 2021
Côte d'Or Breast and Gynecological Cancer Registry, Epidemiology and Quality of Life Research Unit, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, Dijon, France; National Quality of Life and Cancer Platform, Dijon, France.
Purpose: To identify prognostic factors of invasive-disease free survival (iDFS) in women with non-metastatic hormone receptor positive (HR+) breast cancer (BC) in daily routine practice.
Methods: We performed a retrospective study using data from the Côte d'Or breast and gynecological cancer registry in France. All women diagnosed with primary invasive non-metastatic HR + BC from 1998 to 2015 and treated by endocrine therapy (ET) were included.
Health Qual Life Outcomes
February 2021
Epidemiology and Quality of Life Research Unit, Lipids, Nutrition, Cancer Research Center, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, 1 rue Professeur Marion, BP 77980, 21079, Dijon Cedex, France.
Background: With the growing number of older endometrial cancer (EC) and ovarian cancer (OC) survivors, data on long-term health-related quality of life (HRQoL) became an important issue in the management of older patients. So, the aim of this study was to describe and compare according to age long-term HRQoL, sexual function, and social deprivation of adults with either EC or OC.
Methods: A cross-sectional study was set up using data from the Côte d'Or gynecological cancer registry.
Trials
June 2020
Epidemiology and Quality of Life Research Unit, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, 1 rue du Professeur Marion, Dijon Cedex, 21000, France.
Background: Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine therapy (ET) is suboptimal in women with breast cancer (BC). Health-related quality of life (HRQoL) in BC has been widely studied and many positive effects have been highlighted. Recently, a link between HRQoL and compliance with ET has been suggested, which would suggest a potential role for HRQoL assessment in improving compliance with ET.
View Article and Find Full Text PDF